Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study

The Lancet Infectious Diseases

Volumn 17, Issue 7, 2017, Pages 707-715

  Sharma, Aditya ^a   Hill, Andrew ^a   Kurbatova, Ekaterina ^a   van der Walt, Martie ^b   Kvasnovsky, Charlotte ^c   Tupasi, Thelma E ^d   Caoili, Janice C ^d   Gler, Maria Tarcela ^d   Volchenkov, Grigory V ^e   Kazennyy, Boris Y ^f   Demikhova, Olga V ^g   Bayona, Jaime ^h   Contreras, Carmen ^h   Yagui, Martin ⁱ   Leimane, Vaira ^j   Cho, Sang Nae ^k   Kim, Hee Jin ^l   Kliiman, Kai ^m   Akksilp, Somsak ⁿ   Jou, Ruwen ^o   Ershova, Julia ^a   Dalton, Tracy ^a   Cegielski, Peter ^a   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d Tropical Disease Foundation   (Philippines)

^e Vladimir Oblast Tuberculosis Dispensary   (Russian Federation)

^f Orel Oblast Tuberculosis Dispensary   (Russian Federation)

^g CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^h SOCIOS EN SALUD   (Peru)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^k Yonsei University College of Medicine   (South Korea)

^l Korean Institute of Tuberculosis   (South Korea)

^m TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁿ MINISTRY OF PUBLIC HEALTH   (Thailand)

^o CENTER FOR DISEASE CONTROL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARTMENT MODEL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH SURVEY; HUMAN; INDIA; MANAGED CARE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PHILIPPINES; PREDICTION; PRIORITY JOURNAL; RUSSIAN FEDERATION; SOUTH AFRICA; ASIA; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; THEORETICAL MODEL;

ANTITUBERCULAR AGENTS; ASIA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; RUSSIA; SOUTH AFRICA;

EID: 85019150326     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30247-5     Document Type: Article

References (30)

1. WHO. Global tuberculosis report. WHO/HTM/TB/2016.13, 2016, World Health Organization, Geneva.
2. UN. The Millenium Development Goals report, 2014, United Nations, New York.
3. Shah, NS, Abigail, W, Gill-Han, B, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13 (2007), 380–387.
4. Colijn, C, Cohen, T, Ganesh, A, Murray, M, Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One, 6, 2011, e18327.
5. Blower, SM, Chou, T, Modeling the emergence of the hot zones: tuberculosis and the amplification dynamics of drug resistance. Nat Med 10 (2004), 1111–1116.
6. Blower, S, Supervie, V, Predicting the future of XDR tuberculosis. Lancet Infect Dis, 7, 2007, 443.
7. WHO. DOTS-Plus and the Green Light Committee: improving access to second-line anti-TB drugs, 2000, World Health Organization, Geneva.
8. Dalton, T, Cegielski, P, Akksilp, S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 380 (2012), 1406–1417.
9. Cegielski, JP, Dalton, T, Yagui, M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59 (2014), 1049–1063.
10. Kendall, EA, Fofana, MO, Dowdy, DW, Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 3 (2015), 963–972.
11. Menzies, NA, Cohen, T, Lin, HH, Murray, M, Salomon, JA, Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med, 9, 2012, e1001347.
12. UNAIDS. Joint United Nations programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic (UNAIDS/JC2684), 2014, United Nations, Geneva.
13. Fox, GJ, Barry, SE, Britton, WJ, Marks, GB, Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 41 (2013), 140–156.
14. Sloot, R, Schim van der Loeff, MF, Kouw, PM, Borgdorff, MW, Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 190 (2014), 1044–1052.
15. Selwyn, PA, Hartel, D, Lewis, VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320 (1989), 545–550.
16. Tiemersma, EW, van der Werf, MJ, Borgdorff, MW, Williams, BG, Nagelkerke, NJ, Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV-negative patients: a systematic review. PLoS One, 6, 2011, e17601.
17. National Tuberculosis Institute. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 51 (1974), 473–488.
18. Seung, KJ, Gelmanova, IE, Peremitin, GG, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 39 (2004), 1321–1328.
19. El-Sadr, WM, Perlman, DC, Denning, E, Matts, JP, Cohn, DL, A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 32 (2001), 623–632.
20. Khan, FA, Minion, J, Pai, M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 50 (2010), 1288–1299.
21. Houben, RM, Glynn, JR, Mboma, S, et al. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. AIDS 26 (2012), 2233–2239.
22. Anglaret, X, Minga, A, Gabillard, D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 54 (2012), 714–723.
23. Gabillard, D, Lewden, C, Ndoye, I, et al. Mortality, AIDS morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. JAIDS 62 (2013), 555–561.
24. Lew, W, Pai, M, Oxlade, O, Martin, D, Menzies, D, Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149 (2008), 123–134.
25. Alvarez-Uria, G, Pakam, R, Midde, M, Naik, PK, Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc, 17, 2014, 19251.
26. Arentz, M, Pavlinac, P, Kimerling, ME, et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One, 7, 2012, e47370.
27. Weis, SE, Slocum, PC, Blais, FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 330 (1994), 1179–1184.
28. Wilson, E, Probable inference, the law of succession, and statistical inference. J Am Stat Assoc, 22, 1927, 209.
29. Gagneux, S, Long, CD, Small, PM, Van, T, Schoolnik, GK, Bohannan, BJ, The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312 (2006), 1944–1946.
30. Grandjean, L, Gilman, RH, Martin, L, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. PLoS Med, 12, 2015, e1001843.